Merck & Co. (MRK) delivered mixed results in FY2026 on revenue of $104.0B versus the $102.5B estimate (+18.3% YoY) and EPS of $2.96. Below is the full Merck & Co. earnings breakdown — the risk-adjusted verdict, price forecast, technicals, options and hedge-fund 13F holdings, decoded in plain English.
Merck & Co. (MRK) Earnings Analysis — key stats
Next earnings date
Feb 4, 2025
Latest reported quarter
FY2026
Earnings verdict
Mixed
Revenue
$104.0B (vs $102.5B est · +1.5% surprise · +18.3% YoY)
EPS
$2.96 (vs $3.06 est · -3.3% surprise · +6.0% YoY)
Share price
$250.88 (+2.9%)
Market cap
$1.25T
What you'll find
Next Merck & Co. (MRK) earnings date, the expected move and the estimates priced in
A clear Beat / Miss / In-line / Mixed verdict the moment Merck & Co. reports
Revenue & EPS versus estimates, guidance and segment trends
Multi-lens price forecast — analyst, quant, technical and options views
Deep research: red flags, risk decoder and earnings-call sentiment
Technicals, options / implied volatility and unusual-activity signals
Hedge-fund and legendary-investor 13F holdings in Merck & Co. (MRK)
Side-by-side peer and historical earnings comparison
Frequently asked questions
When is Merck & Co.'s next earnings date?
Merck & Co.'s (MRK) next scheduled earnings date is Feb 4, 2025. Magnisto shows the confirmed date, the options-implied expected move and the revenue and EPS estimates Wall Street is modeling into the report.
Did Merck & Co. (MRK) beat or miss earnings?
In FY2026, Merck & Co. (MRK) posted mixed results — revenue of $104.0B versus the $102.5B estimate (+1.5% surprise) and EPS of $2.96 versus $3.06 expected (-3.3% surprise). Magnisto decodes every Merck & Co. (MRK) report into a clear Beat, Miss, In-line or Mixed verdict and checks whether guidance was raised, held or cut.
What is the forecast for Merck & Co. (MRK) stock?
Magnisto blends analyst price targets, quantitative research, technical trend and options-implied moves into a scenario range for Merck & Co. (MRK), anchored to the current $250.88 share price, so you can weigh the bull, base and bear cases for Merck & Co. side by side.
Is Merck & Co. (MRK) a buy right now?
Magnisto does not give buy or sell tips. It gives you the institutional-grade evidence — the verdict, valuation, risks, technicals and hedge-fund 13F flows — so you can decide whether Merck & Co. fits your own thesis and risk profile. This is research, not investment advice.